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Molecular genetic analysis offers opportunities to advance our understanding of the
nosological relationship between psychiatric diagnostic categories in general, and the mood
and psychotic disorders in particular. Strong evidence (P=7.010
7) of association at the
polymorphism rs1006737 (within CACNA1C, the gene encoding the a-1C subunit of the L-type
voltage-gated calcium channel) with the risk of bipolar disorder (BD) has recently been
reported in a meta-analysis of three genome-wide association studies of BD, including our BD
sample (N=1868) studied within the Wellcome Trust Case Control Consortium. Here, we have
used our UK case samples of recurrent major depression (N=1196) and schizophrenia
(N=479) and UK non-psychiatric comparison groups (N=15316) to examine the spectrum of
phenotypic effect of the bipolar risk allele at rs1006737. We found that the risk allele conferred
increased risk for schizophrenia (P=0.034) and recurrent major depression (P=0.013) with
similar effect sizes to those previously observed in BD (allelic odds ratio B1.15). Our findings
are evidence of some degree of overlap in the biological underpinnings of susceptibility to
mental illness across the clinical spectrum of mood and psychotic disorders, and show that at
least some loci can have a relatively general effect on susceptibility to diagnostic categories,
as currently defined. Our findings will contribute to a better understanding of the pathogenesis
of major psychiatric illness, and such knowledge should be useful in providing an etiological
rationale for shaping psychiatric nosology, which is currently reliant entirely on descriptive
clinical data.
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Introduction
The nature of the relationship between mood and
psychotic illness has been an area of debate in
psychiatry since the birth of the specialty. Within
the family members of a proband with bipolar
disorder (BD), there is an increased risk (above the
level in the general population) of unipolar recurrent
depression,
1 and twin studies show that this is in part
explained by shared genetic susceptibility.
2 Further-
more, family studies show that schizophrenia is more
common than expected within the families of bipolar
probands,
3–5 although the risk is less pronounced
than for unipolar depression. A recent twin study
showed the existence of shared genetic susceptibility
to mania and schizophrenia syndromes,
6 suggesting
that there may also be some shared genetic suscept-
ibility to schizophrenia and BD.
Molecular genetic analysis offers the opportunity to
test specific biological genetic hypotheses that can
inform our understanding of the nosological relation-
ship between diagnostic categories in general, and the
mood and psychotic disorders in particular. A recent
meta-analysis of genome-wide association studies on
BD
7 provides such an opportunity. A strong associa-
tion signal was identified within CACNA1C, the gene
encoding the a-1C subunit of the L-type voltage-gated
calcium channel gene (signal maximal at rs1006737;
P=7.010
–8). An association signal was present at
this polymorphism, with the same risk allele, in each
of the three separate component BD samples.
7–9
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8 BD dataset, the significance level was
P=7.010
–4.
Here, we have used samples from the UK popula-
tion recruited and assessed clinically using a meth-
odology similar to that used for our WTCCC BD
samples to test the hypotheses that (i) this risk allele
is associated with the risk of recurrent major depres-
sion, (ii) the risk allele is associated with the risk of
schizophrenia.
Methods
Samples
All of the participants in these studies were unrelated,
white, living in the British Isles and were of European
descent. The protocols and procedures were approved by
the relevant ethics review panels where patients were
recruited. Cases were excluded if they: (i) had only
experienced mood or psychotic illness as a result of
alcohol or substance dependence; (ii) had a history of
intravenous drug use; (iii) had only experienced mood or
psychotic illness secondary to medical illness or medica-
tion; or (iv) were biologically related to another study
participant. A similar methodology was used for assess-
ment of bipolar, unipolar and schizophrenia cases: a semi-
structured lifetime psychiatric interview (Schedules for
Clinical Assessment in Neuropsychiatry),
10 ar e v i e wo ft h e
available case notes and completion of the Operational
Criteria (OPCRIT) checklist of items of psychopathology,
11
followed by a consensus best-estimate lifetime diagnosis
according to the Diagnostic and Statistical Manual of the
American Psychiatric Association (DSM-IV) criteria
(American Psychiatric Association 1994).
12
BD cases
The 1868 WTCCC BD cases (37% male, mean age 47
(s.d. 13) years, mean age at onset 26 (s.d. 11) years,
lifetime experience of psychotic symptoms in 66%
and lifetime experience of mood-incongruent psycho-
tic symptoms in 47% of the cases) have been
previously described
8 and further details of clinical
methodology can be found elsewhere.
13,14
Unipolar recurrent major depression cases
In addition to the exclusion criteria described above,
unipolar cases were also excluded if they (i) had a
first- or second-degree relative with a diagnosis of
bipolar affective disorder or schizophrenia, schizoty-
pal disorder, persistent delusional disorder, acute and
transient psychotic disorders, or schizoaffective dis-
order (all of which increase the likelihood of devel-
oping BD or a psychotic disorder); or (ii) had ever
experienced mood-incongruent psychosis or psycho-
sis outside of mood episodes.
All cases met the DSM-IV
12 criteria for recurrent
unipolar major depressive disorder (1196 cases, 31%
male, mean age 47 (s.d. 12) years, mean age at onset 23
(s.d. 12) years; further information on key variables
was available for 348 individuals, 13% of whom had a
lifetime occurrence of one or more mood congruent-
psychotic features).
Schizophrenia cases
The schizophrenia case sample consisted of 479
unrelated participants meeting the DSM-IV criteria
for schizophrenia (68% male, mean age 44.8 (s.d.
13.1) years, mean age at onset 23.8 (s.d. 7.9) years,
lifetime episode of mania in 4% and lifetime episode
of depression in 23% of the participants). The sample
is described elsewhere.
15
WTCCC controls
There were 2938 controls recruited from England,
Wales and Scotland, who were not screened to
exclude the presence of psychiatric illness, and who
came from two sources, as described.
8
1958 Birth Cohort controls: 1480 controls came
from the 1958 Birth Cohort (also known as the
National Child Development Study), which includes
all births in England, Wales and Scotland during 1
week in 1958. Age at recruitment was 40–49 years;
50% were male.
UK Blood Services controls: The second set of
controls was comprised 1458 individuals selected
from a sample of blood donors recruited as part of the
WTCCC current project. Their age range was 18–69
years; 48% were male.
Expanded reference sample
Consistent with the methodology introduced and
described within the WTCCC study,
8 an additional
source of comparison samples from the UK popula-
tion was provided by the non-BD disease samples
studied within the WTCCC (coronary artery disease,
Crohn’s disease, hypertension, rheumatoid arthritis,
type I and type II diabetes). In total, this sample
comprised 11373 individuals; 49% were male. These
samples were not screened for psychiatric illness.
Additional controls typed within the Cardiff laboratory
In addition to the WTCCC controls and expanded
reference sample typed within the WTCCC, we used
additional UK controls from two sources.
GENESiS controls:( N=681, 42% male, mean age 47
(s.d. 9) years) were a subsample of participants who
had originally been recruited to the GENESiS (Genetic
and Environmental Nature of Emotional States in
Siblings) study
16 through general practices in England
and Wales. GENESiS participants were approached to
take part in the current study if they fell into the
bottom 20% of the distribution on the Sham Compo-
site Index of Liability to Depression and Anxiety.
16
Controls had no current serious medical illness or
disability and were screened to exclude a personal or
family history of psychiatric illness using a semi-
structured telephone interview. We have used con-
trols from this source in previous molecular genetic
studies.
17
Cardiff controls:( N=378, 31% male, mean age 41
(s.d. 15) years) were recruited from two sources. One
source was the British Blood Transfusion Service.
This sample (N=269) was not specifically screened
for psychiatric illness, but individuals were not
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Kingdom, blood donors are not remunerated even for
expenses and are, therefore, not overrepresented for
indigents or the socially disadvantaged, in whom the
rate of psychosis might possibly rise above a thresh-
old that would the influence power.
18 The second
source comprised individuals who were recruited
from among those attending family practitioner
clinics for non-psychiatric reasons. This sample
(N=109) was screened to exclude a personal or
family history of mood disorder. We have used
controls from these two sources extensively in
previous molecular genetic studies
13,14 and have not
observed evidence for heterogeneity between the
control sets nor systematic differences in genetic
background from our case samples.
13
Genotyping
Affymetrix 500K array. rs1006737 was genotyped as
part of the WTCCC genome-wide association study
(GWAS)
8 in the BD cases, WTCCC controls and in the
six other disease cohorts that comprise the expanded
reference sample. Further, the schizophrenia cases
were genotyped using the same pipeline and at the
same time as the WTCCC disease and control
samples.
15 The GWAS genotyping is described in
detail elsewhere.
8 All genotyping was undertaken
using the GeneChip 500K Mapping Array Set at the
Affymetrix service laboratory in San Francisco (CA,
USA). Genotype calls were made by members of the
WTCCC consortium using the CHIAMO algorithm
concurrently with the calling of all the WTCCC
disease and control samples.
Further genotyping of rs1006737 was undertaken
using alternative genotyping platforms (Sequenom
and Amplifluor, San Diego, CA, USA), both to
independently verify the genotypes from the Affyme-
trix assay (using samples typed within WTCCC) and
to extend the genotyping to new cases (recurrent
unipolar depression) and controls. Unipolar cases
(N=1196) and GENESiS controls (N=681), and
subsets of the WTCCC bipolar cases (N=1640) and
controls (N=1351) were genotyped using Sequenom
technology. A subset of the unipolar cases (N=1043)
and GENESiS controls (N=418) that had been
genotyped by Sequenom were further genotyped by
a second independent method, Amplifluor, along
with the additional Cardiff controls (N=378).
Sequenom genotyping. Individual genotyping of
rs1006737 was carried out by Bioserve
Biotechnologies Ltd (Laurel, MD, USA) using the
Sequenom iPLEX Gold system. All plates for
genotyping contained a mixture of cases, controls,
blanks and CEU samples to provide a measure of
genotyping accuracy. All genotypes were called blind
to their sample identity, affection status and genotype
calls obtained using other genotyping methods.
Amplifluor genotyping. Allele-specific PCR using the
Amplifluor system (Invitrogen Ltd, Paisley, Scotland)
was undertaken within the Cardiff laboratory
according to the manufacturer’s instructions, with
alleles being determined by fluorescence polarization
measurement using Analyst (LJL Biosystem Ltd,
Surrey, England). As for genotyping by Sequenom,
DNA plates contained a mixture of cases, controls,
blanks and European Caucasian (CEU) samples, and
the genotypes were called blind to their sample
identity, affection status and genotype calls obtained
using other genotyping methods.
Statistical analysis
Genotype call concordance across platforms was
assessed. Departure from Hardy–Weinberg equilibrium
was tested using a w
2 goodness-of-fit test. Contingency
tables were used to test genotypes and alleles for
differences between sample sets and, where relevant,
to calculate odds ratios and their 95% confidence
intervals. Cochran–Armitage trend tests were per-
formed using Graphpad Instat (www.graphpad.com).
As we were interested in the disease-predisposing
effect of a specific allele, the hypothesis tests included
the direction of effect and we therefore report
one-tailed tests, except where specified.
Consistent with our previous phenotypic analyses of
the WTCCC BD dataset,
19 we undertook an exploratory
analysis using logistic regression to seek one or more
phenotype variables that showed an enhanced signal
at the risk allele. In the bipolar sample, we tested the
following clinical variables: age at onset of illness,
lifetime occurrence of psychosis, Bipolar Affective
Disorder Dimension Scale (BADDS)
20 mania score,
BADDS depression score, BADDS psychosis score,
BADDS incongruence score, lifetime occurrence of
suicidal ideation, lifetime occurrence of rapid cycling
and polarity of onset of illness. In the unipolar sample,
we tested the following clinical variables: age at onset,
lifetime occurrence of psychosis, BADDS depression
score, Global Assessment Scale (GAS) score during the
worst episode and lifetime occurrence of suicidal
behavior. In the schizophrenia sample, we tested the
following clinical variables: age at onset, lifetime
occurrence of a major depressive episode, lifetime
occurrence of a manic episode and lifetime occurrence
of suicidal ideation.
Results
Genotyping quality was excellent, with consistency
between assays
Affymetrix 500K array: Call rate=99.9%; Hardy-
Weinberg Equilibrium (HWE) P-value, P>0.05.
Sequenom: Overall genotype call rate=99.3%;
HWE P-value, GENESiS controls, P>0.05. Genotyp-
ing concordance: three genotype discrepancies were
observed in 2911 genotypes (1321 controls, 1590
bipolar cases) genotyped by both Sequenom and
Affymetrix (concordance rate =99.89%).
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HWE P-value GENESiS controls and Cardiff controls,
P>0.05. Genotyping concordance: one genotype dis-
crepancy was observed in 1315 genotypes (938
unipolar cases, 377 controls) genotyped by both
Amplifluor and Sequenom (concordance
rate=99.92%).
Genotype distributions at rs1006737 were closely
similar in all control and reference sample sets
The genotype distributions at rs1006737 were closely
similar in each of the different control and reference
samples, and there were no significant differences
between any pair-wise comparisons of these control
and reference groups (Supplementary Table 1). The
two additional GENESiS and Cardiff blood donor
control sample sets that were genotyped (that is, those
control data independent of the WTCCC) were, thus,
combined to form a single independent control group
against which the unipolar cases could be compared.
The BD risk allele at rs1006737 was significantly more
common in recurrent depression than in controls or
reference samples
Comparison of the recurrent unipolar depression
cases with the independent new controls showed
significant overrepresentation of the BD risk allele, A
(minor allele), in cases compared with controls
(P=0.013). Similarly, comparison with the WTCCC
expanded reference sample showed significant over-
representation of the A allele in cases with an
increased level of statistical significance
(P=3.910
–4) because of the larger sample size of
the reference sample. See Table 1 and Figure 1.
BD risk allele at rs1006737 was significantly more
common in schizophrenia than controls
Comparison of the schizophrenia cases against the
WTCCC controls (as used in the original study
design
15) showed significant overrepresentation of
the A allele in cases compared with controls
(P=0.034). Similarly, comparison against the WTCCC
Table 1 Genotype and allele distributions and P-values in controls, bipolar, schizophrenia and unipolar disorder cases for the
CACNA1C polymorphism rs1006737
Genotype counts/frequency Allele counts/frequency
n AA AG GG Trend
P-value
A G OR (95% CI)
New controls 1019 112 (11.0) 449 (44.1) 458 (44.9) 673 (33.0) 1365 (67.0)
UP cases 1165 155 (13.3) 535 (45.9) 475 (40.8) 0.013 845 (36.3) 1485 (63.7) 1.15 (1.02–1.31)
Controls (WTCCC) 2636 336 (11.4) 1233 (42.0) 1367 (46.6) 1905 (32.4) 3967 (67.6)
SZ cases 479 66 (13.8) 208 (43.4) 205 (42.8) 0.034 340 (35.5) 618 (64.5) 1.15 (0.99–1.32)
WTCCC expanded
reference
11361 1252 (11.0) 4949 (43.6) 5160 (45.4) 7453 (32.8) 15269 (67.2)
UP cases 1165 155 (13.3) 535 (45.9) 475 (40.8) 3.910
4 845 (36.3) 1485 (63.7) 1.17 (1.07–1.27)
SZ cases 479 66 (13.8) 208 (43.4) 205 (42.8) 0.043 340 (35.5) 618 (64.5) 1.13 (0.98–1.29)
Abbreviations: BP (WTCCC) cases, bipolar disorder cases in the WTCCC analysis; CI, confidence interval; OR, odds ratio; SZ
cases, schizophrenia cases; UP cases, unipolar recurrent major depression cases; WTCCC, Wellcome Trust Case Control
Consortium.
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Figure 1 Odd ratios for CACNA1C polymorphism rs1006737 for cases versus control groups. *P<0.01; ***P<0.001;
******P<10
–6. UP, unipolar recurrent major depression cases; new controls, GENESiS controls and Cardiff controls
combined; SZ, schizophrenia cases; total case set, combined UK bipolar disorder cases, unipolar recurrent major depression
cases and schizophrenia cases; total comparison set, combined WTCCC controls, GENESiS controls and Cardiff controls.
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representation of that allele in cases (P=0.043). See
Table 1 and Figure 1.
Genotype and allele distributions at rs1006737 did not
differ significantly between BD, schizophrenia and
recurrent unipolar depression
Comparison of the genotype and allele distributions
in the three different case samples (BD, schizophrenia
and recurrent unipolar depression) did not show
significant differences (w
2 analysis of 33 and 32
contingency tables, P>0.05).
Exploratory genotype–phenotype analyses using the
risk allele at rs1006737
In the exploratory phenotypic analysis of the BD
sample, of the variables examined, only BADDS
depression score was retained within the logistic
regression model (P=0.016). Comparing the allele
distributions of bipolar cases with BADDS depression
score >59 and those scoring <59 showed that the risk A
allele was significantly associated with depression
score >59 (P=0.007, corresponding clinically to
experiencing at least one episode of major depression
that at least meets the International Classification of
Diseases (ICD10)
22 criteria for ‘severe’ major depression).
Within the unipolar and schizophrenia samples the
logistic model did not identify any variables that were
retained within logistic regression models at P<0.05.
Discussion
We have found that, within our white UK case–
control samples, the BD risk A allele at rs1006737
within the CACNA1C gene is also associated with risk
of recurrent major depression and schizophrenia. The
effect sizes were similar for all diagnostic categories
tested, and we found no statistically significant
differences between the genotype or allele distribu-
tions across the three case sets, although each differed
significantly from the reference (control) individuals.
This association signal had been identified at a
genome-wide significance level (P=7.010
–8)i na
meta-analysis of 4387 BD cases and 6209 controls
7
with evidence for association coming from each of the
component datasets within the meta-analysis. The
significance level for the BD case–control analysis
within the original WTCCC study was P=7.010
–4
(two-tailed). It is of interest to note that, if we were to
combine the UK bipolar, recurrent depression and
schizophrenia cases into one composite mood-psy-
chosis case set (N=3509) and compare the genotype
distribution at rs1006737 with the total UK compar-
ison set (N=15316), the significance of association
would be substantially strengthened (by more than
three orders of magnitude) above that seen in our UK
case–control BD sample (P=3.210
–7, two-tailed),
see Figure 1. If we use the meta-analysis of the three
BD datasets within the Ferreira et al. paper
7 (of which
one is the WTCCC BD sample) and the new data for
unipolar depression and schizophrenia, again the
statistical significance for association is strengthened
(this time by more than an order of magnitude,
P=1.2510
9) compared with that in the BD meta-
analyses reported in the Ferreira et al. paper
7
(P=7.010
8, Supplementary Table 2).
A strength of our study is that we have used cases
ascertained from the UK mental health services and
assessed using a similar clinical methodology, which
includes a semi-structured lifetime psychiatric inter-
view and review of case records. In addition, we have
access to a very large reference set of the UK
individuals, which has been genotyped for the poly-
morphism of interest and which shows closely similar
genotype distributions across the component compar-
ison sample sets (be they blood donor controls, the
1958 Birth Cohort or non-psychiatric disease samples).
A further strength is that the polymorphism of interest
has excellent genotyping quality in the assays used,
with a demonstrated high degree of genotype con-
cordance across platforms, providing confidence in
comparing and combining data across platforms.
Most of the reference individuals used in our study
were not screened to exclude psychiatric illness. This
will tend to reduce the power to identify differences
from cases. Although this is known to have minimal
effect for phenotypes with a lifetime prevalence of
around 1% (such as BD and schizophrenia),
18 it may
be important for phenotypes, such as depression, that
are more common. Despite this possible reduction in
power for our association analysis of depression, in
our study, the comparison of recurrent depression
cases with the reference samples was significant and
the genotype distributions were closely similar
between those controls that had been screened to
exclude psychiatric illness (GENESiS) and the other
(unscreened) controls and reference samples.
It has been hypothesized that some genes will
influence the risk for relatively specific domains of
psychopathology, whereas others will have a more
general influence on the risk.
5,23 At the level of
diagnostic category, our data did not allow us to
discriminate between our BD, unipolar depression
and schizophrenia case sets, suggesting that this locus
contributes a relatively general increase of risk across
the mood-psychosis clinical spectrum.
The only variable that was retained in the explora-
tory genotype–phenotype logistic regression analysis
within the bipolar case set was the BADDS depression
score, with increasing score being more associated
with the risk allele. This raises the possibility that
this locus may particularly influence the depressive
aspects of illness. In other words, it may be that this
locus primarily influences susceptibility to depres-
sion, irrespective of the current diagnostic category
used to classify the individual’s overall clinical
picture. This hypothesis will require testing in
independent, preferably large, BD samples, as
well as in other samples from across the mood-
psychosis spectrum. Given the similar effect sizes
observed within the samples studied here, it can be
expected that a systematic study of very large
Phenotypic expression of variation at CACNA1C
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neuropsychiatric illness—may be necessary to refine
the phenotypic expression at this polymorphism. It is
interesting to note that the recently reported Genetic
Association Information Network (GAIN) consortium
study of recurrent depression reported nominally
significant evidence for association at CACNA1C,
24
although it is important to recognize that the
genotyping platform (and hence, single nucleotide
polymorphism set) differed from that used in the
WTCCC analysis. CACNA1C has not been highlighted
among the top hits in schizophrenia GWAS reported
to date. Publicly available schizophrenia GWAS data
are currently very sparse and, given that the expecta-
tion would be that association signals at CACNA1C
would be modest (and, hence, not among the top
hits),
25 it will be important for systematic meta-
analysis and mega-analysis to be undertaken across
all available datasets.
It can be expected that the early robust associations
that will emerge from GWAS meta-analyses will be
biased towards loci that have a relatively broad
spectrum of phenotypic effect. The reason is that,
with our current reliance on diagnostic categories that
have a wide range of possible clinical picture, it is
inevitable that there will be substantial variation
between the clinical spectrum of cases represented in
samples assembled by different researchers. For
example, important systematic variation may occur
in potentially important variables such as severity,
treatment response, symptom profile, ‘comorbidity’
with other clinical syndromes, functional impair-
ment, familial loading, exposure or environmental
triggers, and so on.
26 Thus, the loci that are likely to
emerge most readily from such samples are those that
confer risk across a broad phenotypic spectrum.
Identification of loci conferring a more specific
phenotypic risk is likely to require different ap-
proaches, such as phenotype refinement
19 and the
use of multiple, large, well-characterized samples.
27,28
In summary, within our UK sample ascertained and
studied clinically using similar methodologies, we
have found that the same risk allele at CACNA1C
increases risk to categorically defined BD, schizo-
phrenia and recurrent major depression. This is a
clear demonstration that there is an overlap in the
biological underpinnings of susceptibility to mental
illness across the clinical spectrum of mood and
psychotic disorders. In addition to contributing to a
better understanding of the pathogenesis of major
psychiatric illness, such knowledge will be useful in
shaping psychiatric nosology to move the field from
reliance on a diagnostic and classification system that
is based only on clinical description and towards a
scheme that better reflects the underlying biology of
the psychiatric entities encountered in our clinics.
This will be of great benefit to patients.
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